BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
|Articles|January 12, 2021
- Pharmaceutical Executive-01-01-2021
- Volume 41
- Issue 1
Pharmaceutical Executive, January 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive January 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
2021 in Focus: Pharm Exec’s Annual Industry Outlookalmost 6 years ago
‘Breakthrough’ Balancing Act: The Decline of the Value Propositionalmost 6 years ago
Prescriber Hesitancy on COVID Vaccinesalmost 6 years ago
More Cloud on the Horizon for Pharmaalmost 6 years ago
A New Year for Sustainable Governancealmost 6 years ago
Bound By Bloodalmost 6 years ago
Pharma in Spotlight as Pandemic Continues in 2021almost 6 years ago
Six Degrees of 2020almost 6 years ago
Why Investing in Tech Education Is Importantalmost 6 years ago
Pharm Exec Hits 40Advertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Rebuilding Clinical Data Workflows for the AI Era
3
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5